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Study objectives: The aim of this analysis was to understand the implications of the GOLD 2011
multidimensional system for the assessment and management of COPD, using data from a real-
world observational study.
Methods: Data were drawn from the Adelphi Respiratory Disease Specific Programme, a cross-
sectional survey of consulting patients in five European countries and in the US undertaken be-
tween June and September 2011. Patients were classified using both the GOLD 2010 and
revised GOLD 2011 criteria, and profiled with regards to demographics, disease characteristics
and treatment patterns.
Results: Information on 3813 COPD patients was collected. Disease characteristics showed a
general tendency to worsen in parallel with worsening of symptoms. When comparing dual
versus single risk criteria, the inclusion of exacerbation history resulted in an increase in the
number of patients in high risk groups. The highest proportions of patients receiving inhaled
corticosteroids (ICS) were in group D. However, a considerable proportion of patients in low
risk groups were receiving ICS/long-acting b2 agonists.
Conclusions: Our analysis confirmed the relationship between higher symptomatic burden,
increased airflow limitation and exacerbation, and further illustrated the importance of
including exacerbation history in the assessment of COPD to identify patients at high risk. Asof Respiratory Medicine J, Odense University Hospital, Sdr Boulevard 29, 5000 Odense C, Denmark.
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730 J. Vestbo et al.based on data from current clinical practice, this study also highlighted the frequent and
potentially inappropriate use of ICS and bronchodilators in patients at low risk of experiencing
exacerbations.
ª 2014 Elsevier Ltd. All rights reserved.Background
Chronic obstructive pulmonary disease (COPD) is a complex
disease characterized by multiple clinical manifestations
arising from COPD as well as comorbidities [1]. The multi-
dimensional nature of COPD has only recently started to be
recognized. Patients with COPD have traditionally been
classified based solely on objective measurements of
airflow limitation, as indicated by forced expiratory volume
in one second (FEV1), which has been shown to be the most
reproducible lung function parameter [2].
However, it has become increasingly clear that airflow
limitation alone does not reflect the true burden of the
disease, as FEV1 reflects some aspects of a single biological
variable (lung function) and correlates poorly with patient-
centered outcomes such as exercise tolerance, dyspnea and
health status [3]. More emphasis has been placed on
symptoms, which are more closely related to health-
related quality of life than airflow obstruction [1,4]. In
addition, the importance of exacerbations has only recently
been fully recognized. The GOLD 2011 Strategy document
recommended that the classification of patients with COPD
should no longer be based solely on spirometric categories,
but should include disease impact on patients (determined
by symptom burden and activity limitation) and risk of ex-
acerbations [5]. This approach results in the classification
of patients in four Groups: A (low risk, less symptoms), B
(low risk, more symptoms), C (high risk, less symptoms),
and D (high risk, more symptoms). As different assessments
can be used to assess symptoms and risk, there are several
ways to derive these GOLD classification groups, and evi-
dence suggests that the choice of symptom measure in-
fluences category assignment [6]. The size of each patient
risk group, defined according to the recent combined
assessment, will vary depending on setting [7,8], and the
patient characteristics within each group are not well
established [1].
The analysis reported here was conducted shortly after
the 2011 Strategy document was published. GOLD docu-
ments published in the interim (in 2013 and 2014) have
reflected recent additions to the scientific literature, but
maintain the same approach of assessing COPD based on
the patient’s level of symptoms, future risk of exacerba-
tions, and degree of airflow limitation [9,10]. We report
here the findings of comparing the previous GOLD 2010
classification [11] with the revised 2011 Strategy using
physician and patient-reported information from patients
diagnosed with COPD. Physicians were recruited in the
Respiratory Adelphi Disease Specific Programmes (DSP), a
multinational, cross-sectional market-research survey that
generates data from current clinical practice [12]. The aims
of this analysis were to determine how patients have been
re-classified by the revised GOLD 2011 Strategy versus theprevious GOLD 2010, profile these patients by evaluating
demographics, disease characteristics and treatment pat-
terns, and discuss the implications for future patient care.Methods
The Respiratory DSP was undertaken between June and
September 2011, with data collected from primary and
secondary care physicians and their patients in the US and
five European countries (France, Germany, Italy, Spain and
the UK). To be eligible to participate, physicians had to
have been qualified for >5 years and 35 years and manage
more than three patients each week. Physicians and pa-
tients provided anonymized data in accordance with Health
Insurance Portability and Accountability Act regulations and
in line with market research guidelines, the European
Pharmaceutical Market Research Association Code of
Conduct.
Each participating physician completed a detailed pa-
tient record form (PRF) for the next six consecutive pa-
tients with COPD who consulted them. Comorbidities were
reported in the PRF by the physician via tick box of 33 pre-
coded conditions. Patients with a concomitant diagnosis of
asthma were excluded. In addition, values for pre and/or
post-bronchodilator FEV1 % predicted and exacerbation
history were collected in the PRF. Exacerbations were
physician-defined, described as a worsening of symptoms
beyond normal day-to-day variations. All tests and treat-
ment decisions were made at the discretion of the physi-
cians. Completion of the PRF took approximately
15e20 min per patient, and physicians were compensated
according to the prevailing market rates.
Participating physicians were also asked to invite all
consecutive patients for whom they completed a PRF to
voluntarily complete a patient self-completion question-
naire (PSC). While not truly random, a consecutive patient
sampling technique avoided physician pre-selection of pa-
tients, as the physicians providing the information had no
control over which of the eligible patients in their care
presented in their clinic during the data collection period.
Using the PSC, patient-reported information about their
disease was gathered, including the impact of their COPD
according to the COPD assessment test (CAT) [13] and
perception of breathlessness via the modified Medical
Research Council (mMRC) dyspnea scale [14]. With CAT,
patients scored eight items (cough, phlegm, chest tight-
ness, breathlessness, activity limitation, confidence, sleep
and energy) on a scale of 0e5 depending on their impact.
The sum of scores for each item gives the patient’s impact
score ranging from 0 (no impact) to 40 (worst possible
impact). With the mMRC, patients were asked to select the
option that best describes their level of breathlessness,
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Figure 1 Distribution of patients from previous GOLD criteria
(pre-2011) into 2011 GOLD groups (using CAT). CAT, COPD
assessment test.
Figure 2 Effect of combining single and dual risk criteria and
symptoms (CAT or mMRC). CAT, COPD assessment test; mMRC,
modified medical research council.
Understanding the GOLD 2011 Strategy 731where 0 Z only breathless after exercising heavily and
4 Z too breathless to leave the house.
Patients were asked to complete the questionnaires
alone, without the help from any healthcare provider, and
to place the completed form in a sealed envelope before
returning it to the physician. All physician and patient re-
sponses were anonymized and aggregated to maintain pa-
tient confidentiality. The questionnaires were designed so
they could be completed without additional instruction or
guidance. While the patient forms were quality checked for
anomalous responses, no audit could be performed to
confirm their accuracy.
Categorical variables were tested using the Fishers exact
or chi-squared test, continuous variables using the t-test or
ANOVA, and ordinal variables using the ManneWhitney or
KruskaleWallis test.
Results
Physicians and patients
A total of 639 physicians equally split between primary care
physicians and pulmonologists were recruited in the Res-
piratory DSP and information on 3813 patients with COPD
was recorded. Self-completion questionnaires were
completed by 2392 patients. A total of 1508 patients had
physician-reported data for all four methods of assessment
collected in the survey: FEV1 % predicted, exacerbation
history, and patient self-reported data for both the mMRC
and CAT. Of 1508 patients, 608 were recruited by primary
care physicians and 900 by pulmonologists.
Proportions of patient classified in each GOLD
group
Using pre-2011 GOLD criteria (FEV1 only), 17% of patients
were classified as having mild (Stage 1) COPD, 63% moder-
ate (Stage 2), 16% severe (Stage 3), and 4% very severe
(Stage 4) COPD.
Using CAT according to the current GOLD 2011 criteria,
10% of patients were classified as Group A, 49% Group B, 1%
Group C, and 40% Group D. Two-thirds of patients classified
as Stage 1 using the pre-2011 GOLD criteria are in Group B
using the current GOLD (CAT) criteria, and 18% are in Group
D; 28% of patients classified as Stage 2 using the old criteria
are also classified as Group D according to the 2011 criteria;
and almost all patients in Stages 3 and 4 using the pre-2011
criteria are in Group D using the current criteria (Fig. 1).
Using the current GOLD 2011 classification system, the
proportion of patients in each group differed according to
the criteria used for risk and symptoms. CAT combined with
either risk criterion (FEV1 % predicted or exacerbation his-
tory) produced a generally similar pattern of patients in
each group, although using exacerbation history, compared
with using FEV1, moved more patients from Group B to
Group D as shown in Fig. 2. mMRC produced a generally
similar pattern of patients in each group irrespective of the
risk criterion used (Fig. 2).
Using dual risk criteria, i.e. FEV1 and exacerbation his-
tory, increased the number of patients in the higher risk
groups (C and D), compared with using a single risk criterion(Fig. 2). Only 11% of patients had a CAT score of <10 (using
combined risk criteria) and therefore few patients fell into
quadrants A or C in the GOLD classification. Using CAT,
therefore, resulted in groups of uneven size.
Stratifying the data by the physician specialty consulted,
physician currently responsible for treatment decisions,
reason for consultation, and time since diagnosis did not
alter the difference in the low versus high symptom groups
with the CAT classification (Data not shown).Characteristics of patients in each GOLD group
There were no major demographic differences across GOLD
Groups A, B and C. Patients in Group D, however, were
732 J. Vestbo et al.older and had a higher disease burden than patients in the
other groups, with more types of symptoms and more
consultations reported (Table 1).
Similar CAT scores were observed in the lower symp-
tomatic burden groups (Groups A and C: 5.6 and 5.4,
respectively); however, clear differences in CAT scores
were observed between the remaining groups such that
Group D was associated with a higher symptomatic burden
compared with Group B (26.1 versus 20.3).
Over 70% of patients in the ‘low risk’ Groups (A and B)
had not experienced an exacerbation in the last 12
months. Of patients in Groups C and D 54% and 85%,
respectively, had experienced an exacerbation in the last
12 months and these groups by definition had the greatest
impairment in lung function (as measured by FEV1 %
predicted). The incidence of hospitalization in the pre-
vious 12 months was also confined to these disease
groups.Table 1 Demography and disease characteristics by GOLD grou
GOLD
A (n Z
Age, years 62.0D
Body mass index, kg/m2 26.3
Age at diagnosis, years 57.5
Time since diagnosis, years 3.8D
Diagnosed in previous 12 months, % 28.1D
FEV1, % predicted 72.1
C,D
Number of individual symptoms in previous 4 weeks 1.5B,D
Number of consultations in previous 12 months 2.3B,D
Number of hospitalizations in previous 12 months 0.1C,D
Comorbidities, %
CV conditions 52.0B,D
Diabetes 6.7B,D
Anxiety 3.4D
Depression 0.8B,D
GERD 6.7
Sleep apnea 1.7
Employment status, %
Employed 73.6
Unemployed 0.0
Retired 22.0
Homemaker 4.3
Receiving long-term disability entitlement 0
Current smokers, % 25.0
Pack years (current and ex-smokers) 30.9D
Number of exacerbations in previous 12 months 0.1B,D
Number of antibiotic-treated exacerbations 0.1B,D
Number of OCS-treated exacerbations 0.1C,D
Physician-perceived severity, % B,D
Mild 58.3
Moderate 41.7
Severe 0.0
Very severe 0.0
EQ-5D utility score 0.94B,D
CAT score 5.6B,D
Data are presented as means; significant (p < 0.05) differen
CV Z cardiovascular; GERD Z gastroesophageal reflux disease; CAT
based on CAT.Patients in Group D experienced the highest mean
number of antibiotic-treated exacerbations and the highest
mean number of oral corticosteroid in the previous 12
months irrespective of treatment regimen (Table 1).
The most common comorbidities in any group were
cardiovascular (CV) disease-related conditions. CV disease
was particularly high in patients in Group B and D. Patients
in Group D also had a higher prevalence of comorbidities
than the other groups for diabetes, anxiety, depression,
and gastroesophageal reflux disease.
Patients with high symptomatic burden (Groups B and D)
had the lowest incidences of employment (50% and 32%,
respectively; p < 0.05 compared with Group A). These
groups were also the only groups to include individuals who
were unemployed (4.9% and 4.3%, respectively) or in
receipt of long-term disability payments (3.8% and 5.2%,
respectively). The highest incidence of retired patients was
observed in Group D (53.5%).p in the overall population.
category
152) B (n Z 739) C (n Z 13) D (n Z 604)
63.5D 60.2 67.3A,B
27.1 26.5 26.5
58.0 52.8 59.2
5.0D 6.3 7.8A,B
24.8D 8.3 8.5A,B
69.5D 51.0A 52.2A,B
2.5A,D 1.4D 4.1A,B,C
3.1A,D 2.7 4.4A,B
0.3D 0.2A 0.5A,B
71.1A,D 38.5D 82.1A,B,C
18.8A,D 0.0 30.0A,B
8.9D 27.3 18.8A,B
8.0A,D 9.1 17.6A,B
12.2 9.1 13.5
3.2 9.1 5.4
50.0 66.6 31.8
4.9 0.0 4.3
37.3 33.3 53.5
4.1 0.0 4.8
3.8 0 5.2
32.3 53.9 35.5
33.6D 22.3D 43.0A,B,C
0.3A,C,D 1.4A,B,C 2.4A,B,C
0.2A,D 0.5D 1.8A,B,C
0.2D 0.5AD 1.6A,B,C
A,D D A,B,C
38.0 46.2 7.8
57.2 38.5 43.4
3.8 15.4 35.2
1.0 0.0 13.6
0.78A,C,D 0.97B,D 0.62A,B,C,D
20.3A,C,D 5.4B,D 26.1A,B,C
ces with other groups are indicated by superscript letter;
Z COPD Assessment Questionnaire. Symptoms assessment was
Understanding the GOLD 2011 Strategy 733Medication use in each GOLD group
When patients were stratified according to the 2011 GOLD
assessment scheme, only a small proportion of patients
were not receiving treatment and these were confined to
Group A (3% corresponding to 1% of the total COPD study
population). Considerable proportions of patients in the low
risk groups were currently receiving inhaled corticosteroids
(ICS)/long-acting b2-agonists (LABA), either alone or in
combination with a long-acting muscarinic antagonist
(LAMA) (Fig. 3). The highest proportions of patients
receiving ICS monotherapy were in Group D, and the lowest
proportions were observed in Group A (Fig. 3). Use of re-
liever medication only (short-acting b2-agonists and short-
acting muscarinic antagonist) was more common in Group
A, compared with Groups B and D (Fig. 3).
Group D patients
Group D patients were subdivided based on the presence of:
(1) high spirometric risk only (n Z 143); (2) history of exac-
erbations risk only (n Z 308); or (3) high spirometric and
history of exacerbation risks (nZ 153). Patientsmeeting both
Group D criteria tended to be older and to have higher CAT
scores (Table 2). All CATcomponents contributed significantly
to the overall CAT score, with ‘confidence in leaving home’
(rZ0.7819), ‘activity limitations’ (rZ0.7564) and ‘tightness
of chest’ (rZ 0.7046) contributing most.
Physicians’ perceptions of disease severity seemed to be
primarily influenced by airflow limitation. Patient-reported
quality of life was markedly impaired in the subgroup with
poor FEV1 and history of exacerbations risk, compared with
the other subgroups. Group D patients (all three categories)
were most likely to be treated with the combination of ICS/
LABA plus a LAMA (Fig. 3). Of the patients in Group D, those
with both high spirometric and history of exacerbations risks
(D3 category) were least likely to be treated with ICS plus
LAMA or LAMA alone (Fig. 3).
Discussion
Using our data set taken from patients diagnosed with
COPD, we were able to determine the proportion ofFigure 3 Proportions of patients receiving different treatment r
onists; LAMA, long-acting muscarinic antagonist; ICS, inhaled cortipatients that fall into the different disease categories ac-
cording to the criteria set out in both the previous and
updated GOLD Strategy document. We could also document
that management of COPD does not follow the most current
recommendations.
The aim of the GOLD combined assessment scheme for
COPD classification was to better reflect the complexity of
COPD in terms of symptoms and risk of future exacerba-
tions, compared with simply measuring airflow limitation
[1]. It is important to note that 18% and 28% of patients
classified using the old COPD guidelines as Stage 1 and 2,
respectively, were re-classified as Group D based on the
updated Strategy document. In addition, when following
the current GOLD 2011 Strategy and using combined risk
criteria (FEV1 <50% or 2 exacerbations in the previous
year) plus CAT, 40% of patients are classified as Group D.
Within Group D, the majority of patients were included due
to exacerbation history alone (51%), while fewer were
included due to FEV1 alone or exacerbation history and FEV1
(24% and 25%, respectively). This shift away from depen-
dence on spirometry and increased focus on exacerbation
history in the updated GOLD classification is likely to reduce
the number of patients whose level of risk is under-
estimated. Interestingly, the fact that Groups A and C were
considerably smaller than B and D when CAT score was used
in conjunction with single or combined risk criteria, may
indicate that physicians do not diagnose patients unless
they are quite symptomatic. It should be noted that our
survey was limited by a lack of persistent post-
bronchodilator values for FEV1; however, this reflects the
true situation in real life COPD care.
When evaluating these results, it is also important to
notice that the application of the GOLD classification sys-
tem to our data set also revealed that the questionnaire
employed to determine symptomatology (CAT or mMRC)
had a major impact on group sizes, as previously shown by
Han et al. when comparing St. George Respiratory Ques-
tionnaire scores with mMRC [6]. CAT, compared with
mMRC, increased the number of patients in the more
symptomatic groups (B and D). It is interesting that only
small numbers of patients were classified as Group C
determined by CAT score, owing to few patients having a
CAT score of <10.egimens in each of the GOLD groups. LABA, long-acting b2 ag-
costeroids.
Table 2 Demography and disease characteristics of subtypes identified in GOLD group D patients.
GOLD group D subtypes
D1. High spirometric
risk but low risk
based on
exacerbation
history (n Z 143)
D2. Low spirometric
risk but high risk
based on
exacerbation
history (n Z 308)
D3. High spirometric
risk and high risk
based on
exacerbation
history (n Z 153)
Age, years 66.5 66.9 68.9
Body mass index, kg/m2 25.1D2 27.5D1,3 25.7D2
Age at diagnosis, years 60.5 58.8 59.1
Time since diagnosis, years 5.6D2,3 8.0D1 9.4D1
Diagnosed in previous 12 months % 16.2 7.1 4.6
FEV1 % predicted 36.3
D2,3 67.5D1 36.4D1
Number of symptoms in previous 4 weeks 2.9D2,3 4.3D1 4.7D1
Number of consultations in previous 12 months 2.6D2,3 4.8D1 5.0D1
Number of hospitalizations in previous 12 months 0.1D3 0.3D3 1.0D1,2
Comorbidities, %
CV conditions 74.1 84.5 85.0
Diabetes 15.4D2,3 32.7D1 38.7D1
Anxiety 13.9 18.4 24.1
Depression 11.5D3 15.8 27.0D1
GERD 12.3 14.3 13.1
Sleep apnea 5.4 4.9 6.6
Employment status, %
Employed 31.9 32.3 30.7
Unemployed 7.4 3.2 3.6
Retired 50.0 55.2 53.3
Homemaker 5.7 4.7 4.4
Receiving long-term disability entitlement 4.9 3.9 8.0
Current smokers, % 32.4 40.9 27.6
Pack years (current and ex-smokers) 38.7D3 42.4 48.2D1
Number of exacerbations in last 12 months 0.4D2,3 2.8D1,3 3.5D1,2
Number of antibiotic-treated exacerbations 0.3D2,3 2.1D1,3 2.5D1,2
Number of OCS-treated exacerbations 0.3D2,3 1.8D1,3 2.5D1,2
Physician-perceived severity, % D2,3 D1,3 D1,2
Mild 7.7 10.5 2.6
Moderate 23.1 66.3 16.3
Severe 49.0 20.3 52.3
Very severe 20.3 2.9 28.8
EQ-5D utility score 0.70D3 0.71D3 0.51D1,2
CAT score 23.6D2,3 25.7D1,3 29.5D1,2
Data are presented as means; significant (p < 0.05) differences with other groups are indicated by superscript letter.
CV Z cardiovascular; GERD Z gastroesophageal reflux disease.
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showed a general tendency to worsen in parallel with
worsening of symptoms, confirming the relationships be-
tween higher symptomatic burden, increased airflow limi-
tation, and increased exacerbation incidence. Indeed, the
majority of patients in Groups A and B did not experience
exacerbations in the previous year, suggesting that, in
agreement with the GOLD 2011 assessment system, their
risk is low. On the other hand, patients assigned to Group D
had more symptoms, consultations, exacerbations, and
hospitalizations, than patients in the other groups. Our
finding with regarding hospitalization has important clinical
implications in light of new evidence showing that the
occurrence of every new severe exacerbation requiring
hospitalization worsens the course of the disease andincreases the risk of a subsequent exacerbation [15]. In
agreement with a recent Danish analysis of 6628 patients
with COPD [7], our analysis showed that a high level of
comorbidities was seen not only in group D but also in Group
B. This finding requires further investigation as it is likely to
alter the prognosis of these patients [7].
Notably, this research demonstrates a conflict between
the current real-world practice and the GOLD 2011 updated
treatment recommendations, which advise the use of ICS
only for patients with severe or very severe airflow limita-
tion and/or 2 exacerbations per year (GOLD Group C and
D) [5,16]. In this analysis, a considerable proportion of low
risk patients (GOLD Group A and B), determined using the
CAT, were using ICS/LABA either alone or in combination
with a LAMA. The cross-sectional design of this study
Understanding the GOLD 2011 Strategy 735allowed for assessment of each patient’s GOLD group ac-
cording to their current presentation and risk. It is possible
that some of these patients were treated appropriately
based on a previous evaluation of high risk status. None-
theless, overtreatment has previously been observed in
clinical trials such as UPLIFT and POET [17,18] and is further
indicated by data from recently reported retrospective
studies demonstrating that drug therapies for COPD are
inappropriately prescribed [19,20].
The referral to COPD management guidelines by physi-
cians has been shown previously to be low [20,21] and
adherence to the GOLD treatment Strategy is far from
optimal [20e22]. Differences observed in actual treatment
given by physicians comparedwith recommendationsmay be
because of physician-perceived severity; a physician may
evaluate a patient as more or less severe based on their
overall clinical judgment,which is then acted on, rather than
guidelines.Our analysis supports this observation; patients in
GroupD,whowere perceived as considerablymore severe by
their physician compared with the other patient groups,
were most likely to be treated with the combination of ICS/
LABA plus a LAMA despite the variable lung function and risk
of exacerbations (based on exacerbation history over the
previous year) across this group of patients. In agreement
with the results published by Lange et al., our Group D pa-
tients had a variable risk of future exacerbations, which
should perhaps be taken into account when planning treat-
ment for these individuals [7]. Prediction of risk of future
exacerbations may be improved by considering multiple as-
sessments; data exist to support the use of recognized
multicomponent indices, for example, in predicting out-
comes [23]. It is important, however, to balance the need for
optimizing risk assessment to guide treatment decisions with
the practical requirement for simple tools that can be used in
everyday practice [24]. Exacerbation history appears to be
the most powerful predictor of future events [25] and the
combined use of lung function and exacerbation history is
suggested to be a useful and pragmatic approach [6,24]. In
the future, biomarkersmay have a role to play in pointing out
those at highest risk as suggested by findings from a general
population sample [26].
In conclusion, our analysis provided a comparison of the
2011 and 2010 GOLD systems in terms of patient classifi-
cation and implication for recommended treatments in
COPD. As our analysis was based on data from current
clinical practice, it will prove valuable in helping physicians
gaining a better understanding of real-world treatment
practices and related key issues that will need to be
addressed, such as appropriate use of bronchodilators and
ICS, if optimal treatment decisions for patients with COPD
are to be achieved in the future.
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